Why Chimeric Therapeutics (ASX:CHM) Is Navigating a Critical Reset

Why Chimeric Therapeutics (ASX:CHM) Is Navigating a Critical Reset — And What Remains of the Pipeline

Sonal Goyal

29 September 2026 05:27 PM AEST

Why Chimeric Therapeutics (ASX:CHM) Is Navigating a Critical Reset — And What Remains of the Pipeline

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Chimeric Therapeutics Limited (ASX:CHM) is an ASX-listed oncology company focused on cell therapy. Its FY26 Preliminary Final Report reveals a difficult year: a loss of $18.8 million, up 80.3% from $10.4 million in FY25, driven primarily by a $9.75 million Impairment of the CLTX intellectual property following the return of that programme to City of Hope, and a further $0.5 million impairment of CDH-17 IP following post-reporting clinical developments. Cash reserves fell to just $800,000 at 30 June 2026.

About the Company

Chimeric Therapeutics Limited is an ASX-listed oncology company developing cell therapy treatments for cancer. The company's clinical pipeline has centred on CAR-T cell therapy — a technology that engineers a patient's own immune cells to recognise and attack cancer cells. Chimeric's Assets have included programmes in haematological malignancies and solid tumours, developed in Partnership with institutions including City of Hope, one of the leading cancer research hospitals in the United States. Cell therapy remains one of the most promising and technically challenging frontiers in oncology.

Recent Development

In its Appendix 4E Preliminary Final Report for the year ended 30 June 2026, Chimeric Therapeutics reported a total loss of $18.8 million. The dominant contributor was a $9.75 million impairment of intellectual property relating to the CLTX programme, which was returned to City of Hope during the year. A further $0.52 million IP impairment related to the CDH-17 programme was recognised following post-reporting clinical developments. The group reported nil Revenue for FY26, compared to $3.97 million in FY25. Cash reserves stood at $800,145 at 30 June 2026, down sharply from $5.76 million in FY25. The group's net liabilities were $7.72 million at year end, compared to net assets of $1.97 million a year earlier.

Share Performance

Chimeric Therapeutics (ASX:CHM) shares are trading at AUD 0.005 on 29 September 2026, up 25% on the day. The sharp daily gain on a very low absolute price (half a cent) reflects the speculative nature of micro-cap biotech stocks where small absolute moves create large percentage changes. With cash reserves of only $800,000, the company's near-term survival depends on its ability to raise additional capital.

Sector Context

CAR-T cell therapy is one of the most important developments in modern oncology, with several products now commercially approved globally. However, development-stage cell therapy companies face enormous attrition risk: the cost of clinical development is substantial, Manufacturing is complex, and clinical trial failures — or decisions to discontinue programmes like CLTX — are common. The CLTX programme's return to City of Hope is a significant clinical setback, though it also reduces ongoing development expenditure. The remaining CDH-17 programme faces further uncertainty following the post-reporting clinical developments that triggered the IP impairment.

Risks and Uncertainty

Chimeric Therapeutics' financial position is critical: with only $800,000 in cash and net liabilities of $7.7 million, the company has very limited runway. An urgent Capital raise is almost certainly required in the near term to sustain operations. The return of the CLTX programme to City of Hope and the CDH-17 impairment have materially reduced the company's pipeline value. Investors must assess whether any remaining clinical assets or corporate opportunities justify the risk at the current stage. The company reported nil revenue in FY26, confirming it is entirely dependent on Capital Markets for funding.

Catalysts to Watch

An announcement of a capital raise to replenish the company's cash reserves is the most urgent near-term development for Chimeric Therapeutics shareholders. Any update on the CDH-17 programme — including clinical development plans, partnership discussions, or further impairment considerations — will be closely watched. Strategic alternatives including merger, acquisition, or asset sale discussions may also emerge as management and the board navigate the company's financial position.

FAQs

Q: What happened to the CLTX programme?

A: The CLTX cell therapy programme was returned to City of Hope, which held the originating intellectual property rights. This decision triggered a $9.75 million non-cash impairment of Chimeric's CLTX IP on its balance sheet, as the intangible asset's carrying value was written down to nil.

Q: How much cash does Chimeric have?

A: At 30 June 2026, Chimeric Therapeutics had cash reserves of $800,145, down sharply from $5.76 million a year earlier. With net liabilities of $7.72 million, the company's financial position is critical and a capital raise appears likely to be needed in the near term.

Q: What is CDH-17 and what happened to it?

A: CDH-17 is another cell therapy programme in Chimeric's portfolio. Post-reporting-date clinical developments (assessed as an adjusting event) triggered a $519,716 impairment of the CDH-17 intellectual property in FY26. The nature of these developments has not been fully disclosed in the Appendix 4E.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.